Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03425643 |
|---|---|
| Brief Title: | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) |
| First Submitted : | February 2, 2018 |
| First Submitted that Met QC Criteria : | February 2, 2018 |
| First Posted : | February 7, 2018 |
| Last Update Submitted that Met QC Criteria : | November 8, 2023 |
| Last Update Posted : | November 13, 2023 |